May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/ Scandinavian Sarcoma Group 1 treatment protocol

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1459-1468

  Serra, Massimo ^a   Pasello, Michela ^a   Manara, Maria Cristina ^a   Scotlandi, Katia ^a   Ferrari, Stefano ^a   Bertoni, Franco ^a   Mercuri, Mario ^a   Alvegard, Thor Andreas ^b   Picci, Piero ^a   Bacci, Gaetano ^a   Smeland, Sigbjørn ^c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Drug resistance; Osteosarcoma; P glycoprotein; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; BONE TUMOR; CHILD; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOADJUVANT THERAPY; OSTEOSARCOMA; P-GLYCOPROTEIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36049026825     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1459     Document Type: Article

References (32)

1. Bieling P, Rehan N, Winkler P, Helmke K, et al: Tumour size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14: 848-858, 1996. (Pubitemid 26085530)
2. Bacci G, Ferrari S, Bertoni F, et al: Histologic response of highgrade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 386: 186-196, 2001.
3. Ferrari S, Bertoni F, Mercuri M, et al: Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 12: 1145-1150, 2001. (Pubitemid 32834497)
4. Bacci G, Longhi A, Ferrari S, et al: Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 9: 171-175, 2002.
5. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
6. Pakos EE and Ioannidis JP: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98: 581-589, 2003. (Pubitemid 36885999)
7. Smeland S, Müller C, Alvegard TA, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39: 488-494, 2003. (Pubitemid 36173693)
8. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Eng J Med 333: 1380-1385, 1995.
9. Baldini N, Scotlandi K, Serra M, et al: P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 17: 629-632, 1999.
10. Serra M, Maurici D, Scotlandi K, et al: Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol 14: 301-307, 1999.
11. Serra M, Scotlandi K, Reverter-Branchat G, et al: Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21: 536-542, 2003.
12. Scotlandi K, Manara MC, Hattinger CM, et al: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 41: 1349-1361, 2005. (Pubitemid 40813013)
13. Chan HS, Grogan TM, Haddad G, DeBoer G and Ling V: Pglycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89: 1706-1715, 1997.
14. Hornicek FJ, Gebhardt MC, Wolfe MW, et al: P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop 373: 11-17, 2000.
15. Park YB, Kim HS, Oh JH and Lee SH: The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24: 307-310, 2001. (Pubitemid 32176313)
16. Pösl M, Amling M, Grahl K, et al: P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study. Gen Diagn Pathol 142: 317-325, 1997.
17. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/ erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17: 2781-2788, 1999. (Pubitemid 29415235)
18. Wunder JS, Bull SB, Aneliunas V, et al: MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 18: 2685-2694, 2000.
19. Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23: 8845-8852, 2005.
20. Enneking WF, Spanier SS and Goodman MA: Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 62: 1027-1030, 1980.
21. Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumour. Cancer 56: 1515-1521, 1985.
22. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A and Franceschi C: The treatment of osteosarcoma of the extremities: Twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer 48: 1569-1581, 1981.
23. Bruland ØS and Pihl A: On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33: 1725-1731, 1997.
24. Bramwell VHC: Osteosarcomas and other cancers of bone. Curr Opin Oncol 12: 330-336, 2000.
25. Bramwell VH: The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 24: 561-571, 1997.
26. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84, 1997.
27. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18: 4016-4027, 2000.
28. Smith MA, Ungerleider RS, Horowitz ME and Simon R: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83: 1460-1470, 1991.
29. Blaney SM, Smith MA and Grem JL: Doxorubicin: role in the treatment of osteosarcoma. In: Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Kluwer Academic Publishers, Boston, pp55-73, 1993.
30. Müller CR, Smeland S, Bauer HC, Saeter G and Strander H: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 44: 475-480, 2005.
31. Manara MC, Serra M, Benini S, et al: Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 24: 365-372, 2004.
32. Pasello M, Hattinger CM, Stoico G, et al: 4-Demethoxy-3′- deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer 41: 2184-2195, 2005.